Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludeoxyglucose F-18

FDA-approved product (injectable, injection), marketed as Fludeoxyglucose F18.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Fludeoxyglucose F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Fludeoxyglucose F-18. Its therapeutic class is shown instead.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Fludeoxyglucose F-18, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli6.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludeoxyglucose F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludeoxyglucose F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients

    NCT06962163 · start 2025-12-05

    Registered record
    Registry ID
    NCT06962163
    Conditions
    Metastatic Breast Cancer
    Interventions
    [68Ga]Ga-PentixaFor PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-12-05
    Completion
    2030-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Intervention[68Ga]Ga-PentixaFor PET/CT
    PhaseNot applicable
    Registry statusRecruiting

  • Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors

    NCT07172503 · start 2025-10-01

    Registered record
    Registry ID
    NCT07172503
    Conditions
    Colorectal Cancer; Gastric Cancer (GC); Pancreatic Cancer
    Interventions
    68Ga-NOTA-GPA33 nanobody
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-10-01
    Completion
    2026-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Gastric Cancer (GC); Pancreatic Cancer
    Intervention68Ga-NOTA-GPA33 nanobody
    PhaseNot applicable
    Registry statusNot yet recruiting

  • 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

    NCT06335069 · start 2025-09-01

    Registered record
    Registry ID
    NCT06335069
    Conditions
    Breast Cancer; Breast Neoplasms; Breast Diseases
    Interventions
    68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2027-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Neoplasms; Breast Diseases
    Intervention68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI
    PhasePhase 2
    Registry statusRecruiting

  • [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

    NCT07215182 · start 2025-08-15

    Registered record
    Registry ID
    NCT07215182
    Conditions
    Malignant Melanoma Stage IV
    Interventions
    [68Ga]Ga-FAPI-46
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-15
    Completion
    2027-02-20
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma Stage IV
    Intervention[68Ga]Ga-FAPI-46
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors

    NCT07301801 · start 2025-06-12

    Registered record
    Registry ID
    NCT07301801
    Conditions
    Malignant Tumors; SSTR2; PET
    Interventions
    Injection of 68Ga-FL-031; Injection of 18F-FDG
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-06-12
    Completion
    2026-09-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Tumors; SSTR2; PET
    InterventionInjection of 68Ga-FL-031; Injection of 18F-FDG
    PhaseEarly phase 1
    Registry statusRecruiting

  • CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors

    NCT06720298 · start 2025-01-01

    Registered record
    Registry ID
    NCT06720298
    Conditions
    Solid Tumor
    Interventions
    18F-FDG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    Intervention18F-FDG
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

    NCT06914999 · start 2024-12-03

    Registered record
    Registry ID
    NCT06914999
    Conditions
    Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions
    Computed Tomography; Fludeoxyglucose F-18; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy; Positron Emission Tomography; Sodium Fluoride F-18
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-12-03
    Completion
    2027-08-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma +12 more
    InterventionComputed Tomography; Fludeoxyglucose F-18; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy +2 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • [68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy

    NCT06982053 · start 2024-05-06

    Registered record
    Registry ID
    NCT06982053
    Conditions
    Colorectal Cancer Control and Prevention; Colorectal Cancer Recurrent; Colorectal Cancer Metastatic; Colorectal Cancer Screening
    Interventions
    Received 68Ga-NOTA-GZP PET scanning
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-05-06
    Completion
    2025-03-31
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Control and Prevention; Colorectal Cancer Recurrent; Colorectal Cancer Metastatic; Colorectal Cancer Screening
    InterventionReceived 68Ga-NOTA-GZP PET scanning
    PhaseNot applicable
    Registry statusCompleted

  • PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

    NCT06385652 · start 2024-04-01

    Registered record
    Registry ID
    NCT06385652
    Conditions
    Multiple Myeloma
    Interventions
    68Ga-NB381
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-04-01
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Intervention68Ga-NB381
    PhaseEarly phase 1
    Registry statusRecruiting

  • 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

    NCT06613269 · start 2024-03-27

    Registered record
    Registry ID
    NCT06613269
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    68Ga-NY104 PET/CT; 18F-FDG PET/CT; Radiation Therapy; Systemic therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-27
    Completion
    2028-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    Intervention68Ga-NY104 PET/CT; 18F-FDG PET/CT; Radiation Therapy; Systemic therapy
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET

    NCT05654675 · start 2024-01-15

    Registered record
    Registry ID
    NCT05654675
    Conditions
    Lung Cancer; Lymphoma
    Interventions
    FDG PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-15
    Completion
    2025-06-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Lymphoma
    InterventionFDG PET/CT
    PhaseNot recorded
    Registry statusRecruiting

  • PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer

    NCT06318234 · start 2024-01-01

    Registered record
    Registry ID
    NCT06318234
    Conditions
    Rectal Cancer
    Interventions
    18F-FAPI，18F-FDG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    Intervention18F-FAPI，18F-FDG
    PhaseNot recorded
    Registry statusUnknown

  • PET Imaging of 68Ga-NOTA-H006 in Malignancy

    NCT06162988 · start 2023-12

    Registered record
    Registry ID
    NCT06162988
    Conditions
    Tumor, Solid
    Interventions
    68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2023-12
    Completion
    2028-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumor, Solid
    Intervention68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

    NCT06383520 · start 2023-09-30

    Registered record
    Registry ID
    NCT06383520
    Conditions
    Malignant Neoplasm of Liver
    Interventions
    68Ga-aGPC3-scFv/Fab
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-09-30
    Completion
    2025-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm of Liver
    Intervention68Ga-aGPC3-scFv/Fab
    PhaseEarly phase 1
    Registry statusRecruiting

  • Predicting Lung Cancer-Associated Cachexia With PET Imaging

    NCT05912465 · start 2023-07-01

    Registered record
    Registry ID
    NCT05912465
    Conditions
    Cachexia; Lung Neoplasm
    Interventions
    Stress Reduction Training
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-07-01
    Completion
    2025-03-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCachexia; Lung Neoplasm
    InterventionStress Reduction Training
    PhaseNot applicable
    Registry statusUnknown